Paradigm Biocapital Advisors LP
NEW YORK, NY · CIK 1855655 · 13F filing filed 2022-08-15
SEC-registered investment adviser since 2021 · limited partnership
- Assets managed$4.5bn
- Staff11 · 6 in investment roles
- Main clients (by assets)Private funds 90%
- Private funds2 (2 hedge) · $4.1bn gross assets
- Form ADV · 2026-08-27SEC adviser record
- Legal entityPARADIGM BIOCAPITAL ADVISORS LP (US)
- Kindhedge funds, futures
- Others nearbyNew York, NY
As an employer
- Offices in1 country
- Private fundshedge 2
$501.5m
reported value
+32.6% vs Q1 2022
23positions
77.7%in top 10
5 new
16 added
1 reduced
7 sold out
vs Q1 2022
Holdings, Q2 2022
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| LEGEND BIOTECH CORP LEGN | $53.8m10.73% | Added +146.9k |
| GLOBAL BLOOD THERAPEUTICS IN GBT | $46.2m9.21% | Added +478.7k |
| MIRATI THERAPEUTICS INC MRTX | $44.3m8.83% | Added +561.6k |
| SIERRA ONCOLOGY INC COM NEW | $44.1m8.79% | Added +30.0k |
| INCYTE CORP INCY | $42.2m8.42% | Added +321.6k |
| ASCENDIS PHARMA A/S SPONSORED ADR | $40.2m8.01% | Added +110.5k |
| UNITED THERAPEUTICS CORP DEL UTHR | $38.4m7.66% | Added +87.4k |
| ARGENX SE ARGX | $33.7m6.71% | New |
| IMMUNOCORE HLDGS PLC IMCR | $24.9m4.97% | Added +168.2k |
| ARVINAS INC ARVN | $21.8m4.34% | Added +26.1k |
| BICYCLE THERAPEUTICS PLC BCYC | $17.6m3.51% | New |
| SYNDAX PHARMACEUTICALS INC SNDX | $16.9m3.36% | Added +174.8k |
| VIRIDIAN THERAPEUTICS INC VRDN | $15.1m3.01% | Added +50.5k |
| MERUS N V MRUS | $10.2m2.04% | Added +202.5k |
| ESPERION THERAPEUTICS INC NE ESPR | $9.0m1.79% | Added +250.8k |
| TG THERAPEUTICS INC TGTX | $8.3m1.66% | New |
| ALPINE IMMUNE SCIENCES INC NVLS | $7.0m1.40% | Added +490.6k |
| ENANTA PHARMACEUTICALS INC ENTA | $7.0m1.40% | New |
| VOR BIOPHARMA INC COM | $6.5m1.29% | Added +409.9k |
| OYSTER PT PHARMA INC OYST | $5.8m1.15% | Added +345.6k |
| GRACELL BIOTECHNOLOGIES INC SPONSORED ADS | $4.3m0.86% | Unchanged |
| LIQUIDIA CORPORATION LQDA | $3.7m0.74% | New |
| C4 THERAPEUTICS INC CCCC | $552.0k0.11% | Reduced -426.3k |
Sold out since Q1 2022
| Security | Value then |
|---|---|
| IVERIC BIO INC OPHT | $15.3m910.4k shares |
| IOVANCE BIOTHERAPEUTICS INC IOVA | $15.1m907.4k shares |
| HORIZON THERAPEUTICS PUB L HZNP | $14.3m136.2k shares |
| ZENTALIS PHARMACEUTICALS INC ZNTL | $13.3m287.6k shares |
| PROTHENA CORP PLC PRTA | $9.8m267.9k shares |
| KYMERA THERAPEUTICS INC KYMR | $9.6m227.0k shares |
| FULCRUM THERAPEUTICS INC FULC | $5.0m213.0k shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| OLEMA PHARMACEUTICALS INC OLMA · 13G · filed 2025-02-14 | 10.0%≈ $92.9m |
| EDGEWISE THERAPEUTICS INC EWTX · 13G · filed 2026-08-14 | 9.5%≈ $415.1m |
| ACHIEVE LIFE SCIENCES INC ACHV · 13G · filed 2026-04-24 | 9.2%≈ $64.7m |
| ASSEMBLY BIOSCIENCES INC ASMB · 13G · filed 2026-08-14 | 7.8%≈ $42.7m |
| VIRIDIAN THERAPEUTICS INC VRDN · 13G · filed 2026-08-14 | 6.1%≈ $123.5m |
| TYRA BIOSCIENCES INC TYRA · 13G · filed 2026-09-17 | 5.8%≈ $110.9m |
| LEXEO THERAPEUTICS INC LXEO · 13G · filed 2026-08-14 | 5.3%≈ $19.4m |
| MBX BIOSCIENCES INC MBX · 13G · filed 2026-06-24 | 5.2%≈ $137.6m |
| SPYRE THERAPEUTICS INC SYRE · 13G · filed 2026-10-01 | 5.1%≈ $395.7m |
| JADE BIOSCIENCES INC JBIO · 13G · filed 2026-07-17 | 5.1%≈ $69.0m |